Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026
Rhea-AI Summary
Moderna (NASDAQ:MRNA) will report fourth quarter 2025 financial results on Friday, February 13, 2026 with a live conference call and webcast at 8:00 a.m. ET. The company will also provide a corporate update during the call.
A live webcast will be available under Events and Presentations in the Investors section of Moderna's website. The archived webcast will be posted about two hours after the call and will remain available for one year.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, MRNA declined 1.48%, reflecting a mild negative market reaction. Argus tracked a peak move of +2.3% during that session. Argus tracked a trough of -9.7% from its starting point during tracking. Our momentum scanner triggered 32 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $300M from the company's valuation, bringing the market cap to $19.97B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MRNA fell 6.09% while key biotech peers like ROIV (-1.77%), HALO (-2.42%), and MDGL (-3.39%) also declined, but momentum scans flagged only RVMD with a sharper -21.83% move. Overall patterns suggest stock-specific pressure rather than a broad sector momentum event.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 20 | Clinical trial update | Positive | +2.8% | Five-year Phase 2b melanoma data showing 49% reduction in recurrence or death. |
| Jan 12 | Business update | Positive | -1.3% | J.P. Morgan presentation with 2025 revenue outlook, expense guidance, and cash levels. |
| Jan 05 | Regulatory submission | Positive | +4.2% | Global filings for mRNA-1010 seasonal flu vaccine based on positive Phase 3 data. |
| Dec 18 | Clinical trial funding | Positive | +1.4% | CEPI commits up to $54.3M for Phase 3 H5 pandemic influenza vaccine trial. |
| Dec 17 | Conference appearance | Neutral | +2.1% | Announcement of presentation slot at J.P. Morgan Healthcare Conference. |
Recent fundamentally positive or strategic updates often saw modest positive price reactions, with one notable divergence on a business and pipeline update.
Over the past months, MRNA news has centered on oncology, vaccines, and strategic business updates. On Jan 20, 2026, strong Phase 2b melanoma data drove a 2.8% gain. Positive influenza vaccine submissions on Jan 5, 2026 coincided with a 4.24% move. CEPI Phase 3 funding news on Dec 18, 2025 and a J.P. Morgan conference appearance also produced gains. The current earnings date notice follows this cadence of event-driven milestones but without new financial figures.
Market Pulse Summary
This announcement simply sets the timing for MRNA’s Q4 2025 results and corporate update, directing investors to a webcast that will remain available for one year. In context, it follows recent oncology, influenza, and business disclosures that shaped expectations around revenue, expenses, and pipeline progress. Key items to watch on the upcoming call include any updates to prior preliminary figures, pipeline timelines, and capital allocation plans relative to those earlier communications.
AI-generated analysis. Not financial advice.
CAMBRIDGE, MA / ACCESS Newswire / January 26, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 13, 2026 to report its fourth quarter 2025 financial results, and provide a corporate update.
A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.
Webcast: https://investors.modernatx.com
The archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.
About Moderna
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.
With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
FAQ
When will Moderna (MRNA) report Q4 2025 results?
What time is Moderna's (MRNA) Q4 2025 earnings call?
Where can I watch Moderna's (MRNA) Q4 2025 webcast?
Will Moderna (MRNA) provide a corporate update during the Q4 2025 call?
When will the archived Moderna (MRNA) webcast be available and for how long?
How can investors access the Q4 2025 earnings materials for Moderna (MRNA)?
